Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9589
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalman, J Men
dc.contributor.authorTonkin, Andrew Men
dc.date.accessioned2015-05-15T22:44:37Z
dc.date.available2015-05-15T22:44:37Z
dc.date.issued1992-09-01en
dc.identifier.citationPacing and Clinical Electrophysiology : Pace; 15(9): 1332-46en
dc.identifier.govdoc1383992en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9589en
dc.description.abstractAtrial fibrillation is a common disorder and the incidence increases with each decade of life. Previously, rheumatic mitral valve disease has been the condition most highly associated with atrial fibrillation. However, with the decreasing incidence of rheumatic heart disease, other conditions have assumed greater importance and now congestive cardiac failure, coronary artery disease, and hypertension are the most commonly associated conditions. Nonrheumatic atrial fibrillation is associated with an approximately five-fold increase in the risk of ischemic stroke and a 5% to 7% yearly risk that increases with age. In addition, atrial fibrillation is associated with an increased incidence of silent cerebral infarction and increased mortality. However, whether atrial fibrillation is independently associated with the risk of stroke or is a marker of underlying cardiac disease is contentious. Until recently, the use of preventive therapy has been controversial. However, data from four recently published, prospective randomized studies clearly support the use of warfarin prophylaxis in nonrheumatic atrial fibrillation. Within the diverse group of patients with nonrheumatic atrial fibrillation there are high and low risk subgroups and identification of these may influence decisions regarding antithrombotic prophylaxis. With a few exceptions, however, this remains an area in which there are contradictory findings in the literature. The role of aspirin for prophylaxis in nonrheumatic atrial fibrillation remains unclear and further evaluation awaits the publication of ongoing studies.en
dc.language.isoenen
dc.subject.otherAtrial Fibrillation.complications.epidemiologyen
dc.subject.otherCerebrovascular Disorders.etiology.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherRisk Factorsen
dc.titleAtrial fibrillation: epidemiology and the risk and prevention of stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitlePacing and clinical electrophysiology : PACEen
dc.identifier.affiliationAustin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages1332-46en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1383992en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.